Diabetology International

, Volume 1, Issue 1, pp 35–41 | Cite as

Efficacy and adverse effects of low-dose nateglinide in early type 2 diabetes: comparison with acarbose in a crossover study

  • Toyoyoshi Uchida
  • Junko Kawai
  • Yoshio Fujitani
  • Ryuzo Kawamori
  • Hirotaka Watada
  • Takahisa Hirose
Original article


Recent studies have suggested that treatment of type 2 diabetes soon after diagnosis of diabetes correlates with a long-term reduction in the risk of macroangiopathy. An open-label prospective crossover trial was performed to compare the efficacy and adverse effects of low-dose nateglinide with those of acarbose. The subjects were 23 early type 2 Japanese diabetic patients who were oral hypoglycemic agent naïve and whose HbA1C levels were 6.0–6.9%. Twelve patients received 90 mg/day of nateglinide and 11 patients received 150 mg/day of acarbose. After 12 weeks of either therapy, the drugs were switched and treatment was continued for another 12 weeks. Each patient was requested to complete a questionnaire on complications after the completion of each treatment. HbA1C decreased from a mean baseline of 6.7 ± 0.2 to 6.4 ± 0.3% with nateglinide and to 6.5 ± 0.3% with acarbose. Decreases of HbA1C in nateglinide were larger than those in acarbose, albeit statistically insignificant (p = 0.073). Symptoms related to hypoglycemia were scarcely observed with either treatment. Abdominal fullness/borborygmi were frequently reported by patients on acarbose but were absent or mild in those on nateglinide. After the completion of the study, most patients favored nateglinide over acarbose. Our results suggest that the effects of low-dose nateglinide on postprandial hyperglycemia of early type 2 diabetes are equivalent to those of acarbose, with the added advantage of minimal side effects.


Postprandial hyperglycemia Glinide Alpha-glucosidase inhibitor Hypoglycemia Adverse effects 


Conflict of interest

This clinical trial received financial support from Daiichi Sankyo. Daiichi Sankyo did not have any influence on the analysis and interpretation of the data. T. Hirose, Y. Fujitani and R. Kawamori have received grant support from Takeda. RK, HW, and TH have also acted as spokespeople for Daiichi Sankyo. RK has received grant support from Nippon Eli Lilly. All of the other authors declare no conflict of interest.


  1. 1.
    The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617–21.CrossRefGoogle Scholar
  2. 2.
    Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486–94.CrossRefPubMedGoogle Scholar
  4. 4.
    Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Mita T, Watada H, Shimizu T, Tamura Y, Sato F, Watanabe T, et al. Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Artheriosclerosis Thromb Vasc Biol. 2007;27:2456–62.CrossRefGoogle Scholar
  6. 6.
    Esposite K, Giugliano D, Nappo F. Marfella R; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110:214–9.CrossRefGoogle Scholar
  7. 7.
    Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, et al. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance rationale and design of the nateglinice and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) Trial. Am Heart J. 2008;156:623–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Kurebayashi S, Watada H, Tanaka Y, Kawasumi M, Kawamori R, Hirose T. Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in cross-over study. Endocr J. 2006;53:213–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23:1660–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Hollander PA, Zheng H, Schwaretz SL, Foley JE, Gatlin MR, Dunning BE, Haas SJ. Importance of early insulin secretion. Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care. 2001;24:983–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Hirose T, Mizuno R, Yoshimoto T. The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects. Endocr J. 2002;49:649–52.CrossRefPubMedGoogle Scholar
  12. 12.
    Uchino H, Niwa M, Shimizu T, Nishiyama K, Kawamori R. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue. Endocr J. 2000;47:639–41.CrossRefPubMedGoogle Scholar
  13. 13.
    Laube H. Acarbose. An update of its therapeutic use in diabetes treatment. Clin Drug Invest. 2002;22:141–56.CrossRefGoogle Scholar
  14. 14.
    Hasche H, Mertes G, Bruns C, Englert R, Genthner P, Heim D, et al. Effects of acarbose treatment in type 2 diabetic patients under dietary training. A multicentre, double-blind, placebo-controlled, 2-year study. Diabetes Nutr Metab. 1999;12:277–85.PubMedGoogle Scholar
  15. 15.
    Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract. 2001;52:193–204.CrossRefPubMedGoogle Scholar
  16. 16.
    Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32:187–92.CrossRefPubMedGoogle Scholar
  17. 17.
    The Diabetes Control Complication Trial/Epidemiology of Diabetes Interventions, Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159–67.CrossRefGoogle Scholar
  18. 18.
    Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.CrossRefPubMedGoogle Scholar
  19. 19.
    ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.CrossRefPubMedGoogle Scholar
  20. 20.
    Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRefPubMedGoogle Scholar
  21. 21.
    Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.CrossRefPubMedGoogle Scholar
  22. 22.
    Holman RR, The NAVIGATOR Study Group, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1463–76.CrossRefPubMedGoogle Scholar
  23. 23.
    Arakawa M, Ebato C, Mita T, Fujitani Y, Shimizu T, Watada H, et al. Miglitol suppresses the postprandial increase in IL-6 and enhances active GLP-1 secretion in viscerally obese subjects. Metabolism. 2008;57:1299–306.CrossRefPubMedGoogle Scholar
  24. 24.
    Miwa S, Watada H, Ohmura C, Tanaka Y, Kawamori R. Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide. Endocr J. 2004;51:393–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Lam KS, Tiu SC, Tsang MW, Ip TP, Tam SC. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study. Diabetes Care. 1998;21:1154–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Scorpiglione N, Belfiglio M, Carinci F, Cavaliere D, De Curtis A, Franciosi M, et al. The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type 2 diabetes mellitus. A model of medicine-based evidence. Eur J Clin Pharmacol. 1999;55:239–49.CrossRefPubMedGoogle Scholar
  27. 27.
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Gao H, Xie C, Wang H, Lin Y, Hong T. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes. Acta Pharmacol Sin. 2007;28:534–9.CrossRefPubMedGoogle Scholar

Copyright information

© The Japan Diabetes Society 2010

Authors and Affiliations

  • Toyoyoshi Uchida
    • 1
  • Junko Kawai
    • 1
  • Yoshio Fujitani
    • 1
    • 2
  • Ryuzo Kawamori
    • 1
    • 2
    • 3
    • 4
  • Hirotaka Watada
    • 1
  • Takahisa Hirose
    • 1
    • 2
  1. 1.Department of Medicine, Metabolism and EndocrinologyJuntendo University Graduate School of MedicineTokyoJapan
  2. 2.Center for Therapeutic Innovations in DiabetesJuntendo University Graduate School of MedicineTokyoJapan
  3. 3.Center for Beta Cell Biology and RegenerationJuntendo University Graduate School of MedicineTokyoJapan
  4. 4.Sportology CenterJuntendo University Graduate School of MedicineTokyoJapan

Personalised recommendations